The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) trial
American Heart Journal,  Clinical Article

This study was designed to determine whether there is incremental clinical benefit of niacin in reducing cardiovascular events in patients who have attained optimal on-treatment levels of low-density lipoprotein cholesterol (LDL-C) with a statin.

Methods
  • Between 2006 and 2010, 8,162 individuals signed consent to be screened, 4,275 began study drug run-in, and 3,414 were randomized to treatment.
  • Mean age at entry was 64 ± 9 years, 85% were men, and 92% were white.
  • All study participants had established CV disease and atherogenic dyslipidemia.
  • Participants received simvastatin (or simvastatin plus ezetimibe) at a dose sufficient to maintain LDL-C at 40 - 80 mg/dL (1.03-2.07 mmol/L) and were randomized to receive extended-release niacin or matching placebo.
  • The primary end point is time to the first occurrence of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, hospitalization for acute coronary syndrome or symptom-driven coronary or cerebral revascularization with average follow-up of 4.1 years.

Results
  • Risk factors were prevalent with 34% having diabetes; 71%, hypertension; and 81%, metabolic syndrome.
  • Most participants had coronary artery disease (92%), whereas 11% had peripheral arterial disease; and 12%, cerebrovascular disease.
  • Previous coronary revascularization occurred in 82%, and 54% reported a prior myocardial infarction.
  • Among participants on a statin at entry (94%), mean baseline LDL-C was 71 mg/dL (1.84 mmol/L); mean high-density lipoprotein cholesterol (HDL-C), 34.9 mg/dL (0.90 mmol/L); and median triglycerides, 161 mg/dL (1.82 mmol/L).

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Cardiology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Cardiology Articles

1 Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation European Heart Journal, September 16, 2014    Clinical Article

2 Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease The American Journal of Cardiology, September 5, 2014    Clinical Article

3 Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion Clinical Therapeutics, August 19, 2014    Clinical Article

4 Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid Journal of Thrombosis and Haemostasis, September 25, 2014    Clinical Article

5 Discontinuation of smokeless tobacco and mortality risk after myocardial infarction Circulation, July 25, 2014    Clinical Article

6 Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel Journal of Clinical Pharmacy and Therapeutics, September 24, 2014    Clinical Article

7 Statin therapy improves long-term survival in non-ischaemic cardiomyopathy: a pooled analysis of 4500 patients Heart, Lung, and Circulation, August 15, 2014    Clinical Article

8 The use of statins to prevent postoperative atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 12 studies Journal of Cardiovascular Pharmacology, September 18, 2014    Review Article

9 Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease The American Journal of Cardiology, August 28, 2014    Clinical Article

10 Minimally invasive direct coronary bypass grafting versus percutaneous coronary intervention for single-vessel disease: A meta-analysis of 2885 patients European Journal of Cardio-Thoracic Surgery, August 14, 2014    Evidence Based Medicine    Review Article    Clinical Article

11 Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials Hypertension, September 29, 2014    Evidence Based Medicine    Review Article

12 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

13 High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from saturn Diabetes Care, September 12, 2014    Clinical Article

14 Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials Heart, Lung, and Circulation, September 15, 2014    Evidence Based Medicine    Review Article    Clinical Article

15 Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials European Journal of Vascular and Endovascular Surgery, September 12, 2014    Evidence Based Medicine    Review Article    Clinical Article

16 Egg consumption and cardiovascular disease among diabetic individuals: a systematic review of the literature Full Text Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, July 30, 2014    Free full text    Review Article

17 Impact of access on TAVI procedural and midterm follow-up: A meta-analysis of 13 studies and 10,468 patients Journal of Interventional Cardiology, September 23, 2014    Review Article    Clinical Article

18 A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial The Lancet, September 19, 2014    Evidence Based Medicine    Clinical Article

19 Thiazide-like/calcium channel blocker agents: a major combination for hypertension management American Journal of Cardiovascular Drugs, September 2, 2014    Clinical Article

20 Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial European Heart Journal, September 10, 2014    Clinical Article

Indexed Journals in Cardiology: American Heart Journal, American Journal of Cardiology, Circulationn, Heartmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close